表观遗传学在癌症中的作用以及肿瘤治疗的靶向疗法

Martha Srinivas, Salunkhe Pratiksha Sanjay, Londhe Pratima Manik, Vishal Bharat Babar, Koppula Maheshwari
{"title":"表观遗传学在癌症中的作用以及肿瘤治疗的靶向疗法","authors":"Martha Srinivas, Salunkhe Pratiksha Sanjay, Londhe Pratima Manik, Vishal Bharat Babar, Koppula Maheshwari","doi":"10.9734/cjast/2024/v43i64383","DOIUrl":null,"url":null,"abstract":"DNA sequence has little bearing on the dynamic and heritable changes to the genome that occur in epigenetics. Both genetic and epigenetic alterations influence the development of cancer. There are several opportunities for therapeutic interventions because epigenetic modifications can be reversed. Many epigenetic drugs are currently used globally to treat conditions including leukemia and myelodysplastic syndrome. Owing to their malleability and vulnerability to outside factors, epigenetic modifiers are becoming intriguing targets for a number of cancer treatments. Recently, a large number of epi-drugs have been developed, and they may find application in clinical situations. The aforementioned initiatives to realize the potential of epigenetic medicines for efficient cancer treatment are summed up in this review. The maintenance of cell identity and the spatial and temporal regulation of gene expression depend on the proper coordination of epigenetic regulators. Both genetic and epigenetic changes contribute to cancer. The development of medications that target epigenetic regulators has advanced significantly over the past few decades, with numerous medications currently under assessment in research studies. In how they could be used to treat cancer. We also go over the preclinical and clinical outcomes of epigenetic medication combination therapies as well as other therapies including immune-based and targeted medicines.","PeriodicalId":505676,"journal":{"name":"Current Journal of Applied Science and Technology","volume":"128 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Epigenetics in Cancer and Targeted Therapies for Oncologic Treatments\",\"authors\":\"Martha Srinivas, Salunkhe Pratiksha Sanjay, Londhe Pratima Manik, Vishal Bharat Babar, Koppula Maheshwari\",\"doi\":\"10.9734/cjast/2024/v43i64383\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"DNA sequence has little bearing on the dynamic and heritable changes to the genome that occur in epigenetics. Both genetic and epigenetic alterations influence the development of cancer. There are several opportunities for therapeutic interventions because epigenetic modifications can be reversed. Many epigenetic drugs are currently used globally to treat conditions including leukemia and myelodysplastic syndrome. Owing to their malleability and vulnerability to outside factors, epigenetic modifiers are becoming intriguing targets for a number of cancer treatments. Recently, a large number of epi-drugs have been developed, and they may find application in clinical situations. The aforementioned initiatives to realize the potential of epigenetic medicines for efficient cancer treatment are summed up in this review. The maintenance of cell identity and the spatial and temporal regulation of gene expression depend on the proper coordination of epigenetic regulators. Both genetic and epigenetic changes contribute to cancer. The development of medications that target epigenetic regulators has advanced significantly over the past few decades, with numerous medications currently under assessment in research studies. In how they could be used to treat cancer. We also go over the preclinical and clinical outcomes of epigenetic medication combination therapies as well as other therapies including immune-based and targeted medicines.\",\"PeriodicalId\":505676,\"journal\":{\"name\":\"Current Journal of Applied Science and Technology\",\"volume\":\"128 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Journal of Applied Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9734/cjast/2024/v43i64383\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Journal of Applied Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/cjast/2024/v43i64383","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

DNA 序列与表观遗传学中基因组发生的动态遗传变化关系不大。基因和表观遗传学的改变都会影响癌症的发展。由于表观遗传学的改变可以逆转,因此存在一些治疗干预的机会。目前,全球有许多表观遗传药物用于治疗白血病和骨髓增生异常综合征等疾病。由于表观遗传修饰易受外界因素的影响,它们正成为一些癌症治疗方法的诱人靶点。最近,大量表观药物被开发出来,并有可能应用于临床。本综述总结了上述为实现表观遗传药物高效治疗癌症的潜力而采取的举措。细胞特性的维持和基因表达的时空调控取决于表观遗传调控因子的适当协调。遗传和表观遗传的变化都会导致癌症。过去几十年来,针对表观遗传调节因子的药物开发取得了长足的进步,目前有许多药物正在接受研究评估。在如何利用它们治疗癌症方面。我们还将介绍表观遗传药物联合疗法以及其他疗法(包括免疫疗法和靶向药物)的临床前和临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Role of Epigenetics in Cancer and Targeted Therapies for Oncologic Treatments
DNA sequence has little bearing on the dynamic and heritable changes to the genome that occur in epigenetics. Both genetic and epigenetic alterations influence the development of cancer. There are several opportunities for therapeutic interventions because epigenetic modifications can be reversed. Many epigenetic drugs are currently used globally to treat conditions including leukemia and myelodysplastic syndrome. Owing to their malleability and vulnerability to outside factors, epigenetic modifiers are becoming intriguing targets for a number of cancer treatments. Recently, a large number of epi-drugs have been developed, and they may find application in clinical situations. The aforementioned initiatives to realize the potential of epigenetic medicines for efficient cancer treatment are summed up in this review. The maintenance of cell identity and the spatial and temporal regulation of gene expression depend on the proper coordination of epigenetic regulators. Both genetic and epigenetic changes contribute to cancer. The development of medications that target epigenetic regulators has advanced significantly over the past few decades, with numerous medications currently under assessment in research studies. In how they could be used to treat cancer. We also go over the preclinical and clinical outcomes of epigenetic medication combination therapies as well as other therapies including immune-based and targeted medicines.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信